bioRxivImmunologyPreprint
Perturbomics of tumor-infiltrating NK cells
L. Peng, P. A. Renauer, L. Ye, L. Yang, J. J. Park, R. D. Chow, Y. Zhang, Q. Lin, M. Bai, A. Sanchez, Y. Zhang, S. Z. Lam, S. Chen
Abstract
Natural killer (NK) cells are an innate immune cell type that serves at the first level of defense against pathogens and cancer. NK cells have clinical potential, however, multiple current limitations exist that naturally hinder the successful implementation of NK cell therapy against cancer, including their effector function, persistence, and tumor infiltration. To unbiasedly reveal the functional genetic landscape underlying critical NK cell characteristics against cancer, we perform perturbomics mapping of tumor infiltrating NK cells by joint in vivo AAV-CRISPR screens and single cell sequencing. We establish a strategy with AAV-SleepingBeauty(SB)- CRISPR screening leveraging a custom high-density sgRNA library targeting cell surface genes, and perform four independent in vivo tumor infiltration screens in mouse models of melanoma, breast cancer, pancreatic cancer, and glioblastoma. In parallel, we characterize single-cell transcriptomic landscapes of tumor-infiltrating NK cells, which identifies previously unexplored sub-populations of NK cells with distinct expression profiles, a shift from immature to mature NK (mNK) cells in the tumor microenvironment (TME), and decreased expression of mature marker genes in mNK cells. CALHM2, a calcium homeostasis modulator that emerges from both screen and single cell analyses, shows both in vitro and in vivo efficacy enhancement when perturbed in chimeric antigen receptor (CAR)-NK cells. Differential gene expression analysis reveals that CALHM2 knockout reshapes cytokine production, cell adhesion, and signaling pathways in CAR- NKs. These data directly and systematically map out endogenous factors that naturally limit NK cell function in the TME to offer a broad range of cellular genetic checkpoints as candidates for future engineering to enhance NK cell-based immunotherapies.
- organism: mouse
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-cell functional genomics of natural killer cell evasion in blood cancers
O. Dufva, S. Gandolfi, … S. Mustjoki·bioRxiv·Aug 22, 2022
- Applying CRISPR-based genetic screens to identify drivers of tumor-cell sensitivity towards NK-cell attack
K. Klein, T. Wang, … W. F. Garcia-Beltran·bioRxiv·Jan 27, 2019
- Evaluation of natural killer cell tumor homing and effector function in response to CDK4/6 and AURKA inhibition in a melanoma tumor-on-a-chip platform
Srija Chakraborty, Connor Durham, … Aleksander Skardal·bioRxiv·Jul 9, 2025
- Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing
Sophie Guia, Aurore Fenis, … Émilie Narni-Mancinelli·Journal for ImmunoTherapy of CancerPeer-reviewed·Mar 1, 2025
- Rapid establishment of a tumor-retained state curtails the contribution of conventional NK cells to anti-tumor immunity in solid cancers
I. W. Dean, C. Y. Lee, … D. R. Withers·bioRxiv·Aug 10, 2023
- Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling
Adam M. Farkas, Dina Youssef, … Nina Bhardwaj·bioRxiv·Apr 30, 2024